Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis

Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In the past 2 decades, advances in cancer therapeutics allowed for a remarkable improvement in terms of survival for patients with metastatic CRC. The advent of targeted therapy, coupled with more efficient c...

Full description

Saved in:
Bibliographic Details
Published in:BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 2016-04, Vol.30 (2), p.95-104
Main Authors: Kassouf, Elie, Tabchi, Samer, Tehfe, Mustapha
Format: Article
Language:English
Subjects:
Antibodies
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Biomarkers
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cancer therapies
Cetuximab - therapeutic use
Chemotherapy
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - metabolism
Confidence intervals
Conflicts of interest
Editing
Funding
Genes, ras - drug effects
Humans
Immunoglobulins
Metastasis
Molecular Medicine
Mortality
Mutation
Mutation - drug effects
Pharmacotherapy
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Review Article
Signal transduction
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In the past 2 decades, advances in cancer therapeutics allowed for a remarkable improvement in terms of survival for patients with metastatic CRC. The advent of targeted therapy, coupled with more efficient chemotherapy regimens, was the pillar achievement that contributed to the success of CRC therapy. Cetuximab and panitumumab, monoclonal antibodies targeting the epidermal growth factor receptor pathway, are the focus of this review since their mechanism of action and efficiency are closely related to the mutational status of a predictive biomarker, the Kristen rat Sarcoma viral oncogene (KRAS). More recently, another biomarker, the neuroblastoma rat sarcoma viral oncogene (NRAS), was found to be as valuable for the refinement of this targeted therapy. The arguments for the use of extended analysis of the RAS gene are thoroughly reviewed because they directly affect the choice of targeted agents and potentially the choice of backbone chemotherapy.
ISSN:1173-8804
1179-190X
DOI:10.1007/s40259-016-0166-5